Keyphrases
Tumor-infiltrating Lymphocytes
100%
Immune-related Adverse Events
50%
Corticosteroids
50%
Tumor Regression
50%
Differential Effects
50%
Inhibitor Resistant
50%
Melanoma
50%
Anti-tumor Necrosis Factor (anti-TNF)
50%
T Cells
50%
Infliximab
25%
Metastatic Melanoma
21%
Clinically Significant
16%
Tumor-specific
16%
Immunology and Microbiology
Tumor-Infiltrating Lymphocytes
100%
Immune Response
68%
Immunity
62%
T Cell
58%
Tumor Necrosis Factor
50%
Dexamethasone
25%
Infliximab
25%
Tumor Cell
18%
Drug Megadose
16%
Medicine and Dentistry
T Cell
50%
Tumor Regression
50%
Tumor Infiltrating Lymphocyte
50%
Melanoma
50%
Immune Response
18%
Metastatic Melanoma
18%
